title: Chemotherapy and immunotherapy of brain tumors: what the epileptologist must know.
abstract: I present an overview of therapy for the most common brain tumors encountered in clinical practice if adult patients. Current therapy paradigms and evolving therapies are reviewed. The introduction of non-enzyme-inducing antiepileptic drugs (NEIADs) has simplified the approach to combined medical treatment of epilepsy and brain tumors, but the major interactions between enzyme-inducing antiepileptic drugs (EIAEDs) are included, to serve as guidance in selecting these medications if they are required.
authors: Department of Neurology, Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, Ohio, U.S.A.
authors: Lisa R
authors: LR
authors: Rogers
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000150:complications / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D004827:Epilepsy / Q000209:etiology*; D005910:Glioma / Q000150:complications / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy; D009364:Neoplasm Recurrence, Local / Q000628:therapy; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents
keywords: Bevacizumab; CNS neoplasm; Glioma; O6-methylguanine DNA methyltransferase; Temozolomide